-- 摩根士丹利周三在一份电子邮件报告中指出，富兰克林资源公司 (BEN) 正展现出“早期复苏”的迹象，核心资金流入的改善和西部资产管理公司 (Western Asset Management) 资金流出的缓解增强了其业务增长势头。 这家投资银行表示，富兰克林资源公司已连续九个季度实现“净正流入”（不包括西部资产管理公司），而与西部资产管理公司相关的季度资金流出已从一年前约680亿美元的峰值降至约40亿美元。 报告指出，富兰克林资源公司“向高增长领域重新定位”，包括独立管理账户、ETF和另类投资，正在帮助其稳定“发展轨迹”，但“费用压缩”和向“低费用产品”的转型仍然是结构性挑战。 摩根士丹利将富兰克林资源公司的评级从“减持”上调至“中性”，并将目标价从21美元上调至31美元，理由是“资金流动动态”的改善和风险回报状况的更加平衡。
Price: $31.13, Change: $+0.67, Percent Change: +2.20%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%